详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

A DNA Damage Response Related Signature to Predict Prognosis in Patients with Acute Myeloid Leukemia

108| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]School of Clinical Medicine, Chengdu Medical College, Chengdu, China. [2]School of Clinical Medicine, University of Electronic Science and Technology of China, Chengdu, China. [3]Department of Hematology, Dong Li Hospital, Chengdu, China. [4]Department of Hematology, Chengdu Second People's Hospital, Chengdu, China. [5]Department of Hematology, Chengdu BOE Hospital, Chengdu, China. [6]Burning Rock Biotech, Guangzhou, China. [7]Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China. [8]Department of Clinical Trial, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. [9]Department of Hematology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

出处：

DOI：

ISSN：

关键词： DNA damage response (DDR) ADE regimen gemtuzumab ozogamicin acute myeloid leukemia (AML) prognostic signature treatment selection

摘要：

The prognosis of acute myeloid leukemia (AML) is disappointing in most subtypes and varies widely. DNA damage response (DDR) is associated with prognosis and immunotherapy in multiple cancers. Here, we identify a signature of eight DDR-related genes associated with overall survival, which stratifies AML patients into high- and low-risk groups. Patients in low-risk group were more likely to respond to sorafenib. The signature could be an independent prognostic predictor for patients treated with ADE and ADE plus gemtuzumab ozogamicin. Therefore, this DDR prognostic signature might be applied to prognostic stratification and treatment selection in AML patients, which warrants further studies.

基金：

基金编号： No. 2021LY16

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2023]版：

Q3 ONCOLOGY

最新[2023]版：

Q3 ONCOLOGY

影响因子： 1.8 最新[2023版] 2.1 最新五年平均 1.8 出版当年[2023版] 2.1 出版当年五年平均 2.4 出版前一年[2022版]

第一作者：

第一作者机构： [1]School of Clinical Medicine, Chengdu Medical College, Chengdu, China.

共同第一作者：

通讯作者：

通讯机构： [9]Department of Hematology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. [*1]Department of Hematology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia [2]The crosstalk between DNA-damage responses and innate immunity [3]When DNA-damage responses meet innate and adaptive immunity [4]Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature [5]A Practical Prognostic lncRNA Signature for Lung Squamous Cell Carcinoma [6]Characterization of a prognostic four-gene methylation signature associated with radiotherapy for head and neck squamous cell carcinoma [7]A novel prognostic model based on three integrin subunit genes-related signature for bladder cancer [8]Development and validation of a combined hypoxia and ferroptosis prognostic signature for breast cancer [9]Novel radiomic signature as a prognostic biomarker for locally advanced rectal cancer. [10]Discovery of Prognostic Signature Genes for Overall Survival Prediction in Gastric Cancer.